Leukemia Research
Volume 27, Issue 7 , Pages 655-660 , July 2003

Expression of serologically identified tumor antigens in acute leukemias

  • Philipp Niemeyer

      Affiliations

    • Department of Internal Medicine, Saarland University, D-66424 Homburg, Saar, Germany
    • ,
  • Özlem Türeci

      Affiliations

    • Department of Internal Medicine, III. Medizinische Klinik und Poliklinik, Johannes Gutenberg Universität Mainz, Obere Zahlbacherstr. 63, D-55113 Mainz, Germany
    • ,
  • Thomas Eberle

      Affiliations

    • Department of Internal Medicine, Saarland University, D-66424 Homburg, Saar, Germany
    • ,
  • Norbert Graf

      Affiliations

    • Department of Pediatrics, Saarland University, D-66424 Homburg, Saar, Germany
    • ,
  • Michael Pfreundschuh

      Affiliations

    • Department of Internal Medicine, Saarland University, D-66424 Homburg, Saar, Germany
    • ,
  • Ugur Sahin

      Affiliations

    • Department of Internal Medicine, III. Medizinische Klinik und Poliklinik, Johannes Gutenberg Universität Mainz, Obere Zahlbacherstr. 63, D-55113 Mainz, Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49-6131-3933-488; fax: +49-6131-3933-364.

Received 12 July 2002 ,Accepted 28 September 2002.

References 

  1. Hoelzer D, Gökbuget N, Arnold R, Bücner T, Freund M, Gaßmann W, et al.  Akute lymphatische Leukämie des Erwachsenen. Internist. 1996;387:94–1007
  2. Gokbuget N, Arnold R, Buchner T, Freund M, Gassmann W, Heil G, et al.  Treatment of adult acute lymphoblastic leukemia. Schweiz Rundsch Med Prax. 1999;88:407–420
  3. Marchand M, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999;80:219–230
  4. Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, et al.  Identification of NY-ESO-1 Epitopes presented by human histocompatibility Antigen (HLA)-DRB4*0101-0103 and recognized by CD4+ T Lymphocytes of patients with NY-ESO-1 expressing melanoma. J. Exp. Med. 2000;191:625–630
  5. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med. 1998;187:1349–1354
  6. Chen YT, Old LJ. Cancer-testis antigens, targets for cancer immunotherapy. Cancer J Sci Am. 1999;5:16–17
  7. Van der Bruggen P, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, et al.  A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. Science. 1991;254:1643–1647
  8. Boel P, Wildmann C, Sensei ML, Brasseur R, Renauld M, Coulie P, et al.  BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 1995;2:167–175
  9. van den Eynde B, de Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 1995;182:689–698
  10. Sahin U, Türeci Ö, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al.  Human neoplasms elicit multiple immune response in the autologous host. Proc. Natl. Acad. Sci. USA. 1995;92:11810–11813
  11. Türeci Ö, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Molec. Med. Today. 1997;3:342–349
  12. Türeci Ö, Sahin U, Schobert I, Koslowski M, Schmitt H, Schild HJ, et al.  The SSX-2 gene, which is involved in the t (X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res. 1996;56:4766–4772
  13. Türeci Ö, Chen YT, Sahin U, Gure AO, Zwick C, Villena C, et al.  Expression of SSX genes in human tumors. Int. J. Cancer. 1998;77:19–23
  14. Güre AO, Tuereci O, Sahin U, Tsang S, Scanlan M, Jäger E, et al.  SSX: a multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer. 1997;72:965–971
  15. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94:1914–1918
  16. Türeci Ö, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc. Natl. Acad. Sci. USA. 1998;95:5211–5216
  17. Shichijo S, Tsunosue R, Masuoka K, Natori H, Tamal M, Miyajima J, et al.  Expression of the MAGE gene family in human lymphatic leukemia. Cancer Immunol Immunother. 1995;41:95–103
  18. Chambost H, van Baren N, Brasseur F, Olive D. MAGE-A genes are not expressed in human leukemias. Leukemia. 2001;15:1769–1771
  19. Schichijo S, Sagawa K, Brasseur F, Boon T, Itoh K. MAGE-1 gene is expressed in T-cell leukemia. Int J Cancer. 1996;65:709–710
  20. Chambost H, Brasseur F, Coulie P, de Plaen E, Stoppa AM, Baume D, et al.  A tumour-associated antigen expression in human haematological malignancies. Br J Haematol. 1993;84:524–526
  21. Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, et al.  NY-ESO-1 119–143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002;62:213–218
  22. Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA. 2001;98(7):3964–3969
  23. Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol. 2000;165:1153–1159
  24. Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol. 1998;161:3598–3606
  25. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, et al.  Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187:265–270
  26. Ayyoub SS, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, et al.  Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J. Immunol. 2002;168:1717–1722
  27. Sahin U, Türeci Ö, Chen YT, Seitz G, Villena C, Old LJ, et al.  Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int. J. Cancer. 1998;78:387–389
  28. Nestle FO, Gilliet M, Sun Y, Grappe S, Dummer R, Burg G, et al.  Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. 1998;Med.4:328–332
  29. Rosenberg SA, Schwarzhuber DR, Hwu P, Marincola FM, Topalian SL, Restifo NP, et al.  Immunologic and therapeutic evaluation of synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998;4:321–327

PII: S0145-2126(02)00230-8

doi: 10.1016/S0145-2126(02)00230-8

Leukemia Research
Volume 27, Issue 7 , Pages 655-660 , July 2003

Article Tools

* Image Usage & Resolution